Non-alcoholic fatty liver disease: A brief review

Scandinavian Journal of Gastroenterology, Supplement

Volumn 39, Issue 241, 2004, Pages 56-59

  Van Hoek, B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus; Hepatitis; Insulin resistance; Metformin; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity; Oxygen radicals; Steatosis; Ursodeoxycholic acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BETAINE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; METFORMIN; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; S ADENOSYLMETHIONINE; SCAVENGER; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ALCOHOL ABUSE; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENZYME BLOOD LEVEL; FATIGUE; FATTY LIVER; HEPATOMEGALY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PAIN; PATHOGENESIS; PRIORITY JOURNAL; SYMPTOM; DISEASE COURSE; LIVER FUNCTION TEST; PROGNOSIS; REVIEW; RISK FACTOR;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; LIVER FUNCTION TESTS; PROGNOSIS; RISK FACTORS;

EID: 11144235580     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.1080/00855920410011013     Document Type: Conference Paper

References (58)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
2. Diehl AM. Nonalcoholic steatohepatitis. Sem Liv Dis 1999;19: 221-9.
3. McCullough AJ. Update on non-alcoholic fatty liver disease. J Clin Gastroenterol 2002;34:155-62.
4. AGA Clinical Practice Committee, AASLD Practice Guidelines Committee. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123:1702-4.
5. AGA Clinical Practice Committee, AASLD Practice Guidelines Committee. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
6. Goodman JI. Hepatomegaly and diabetes mellitus. Ann Intern Med 1953;39:1077.
7. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9.
8. Batman PA, Scheuer PJ. Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 1985;9:237.
9. Van Hoek B. Non-alcohol steatohepatitis: state-of-the-art. Br Med J 2001;16 Suppl:28(IX)-28(X).
10. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR 1998;171:659-64.
11. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Sem Liver Dis 2001;21:71-80.
12. Raptopoulos V, Karellas A, Bernstein J, Reale FR, Constantinou C, Zawacki JK. Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses. Am J Roentgenol 1991;157:721.
13. Levenson H, Greensite F, Hoefs J, Friloux L, Applegate G, Silva E, et al. Fatty infiltration of the liver: quantitation with phase-contrast MR imaging at 1.5 T vs biopsy. Am J Roentgenol 1991; 156:307-12.
14. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45.
15. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis. Hepatology 1990;11:74-80.
16. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999;30:1356-62.
17. Latry P, Bioulac-Sage P, Echinard E, Gin H, Boussarie L, Grimaud JA, et al. Peri-sinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients. Hum Pathol 1987;18:775.
18. Lee RG. Nonalcoholic steatohepatitis. Human Pathol 1989;20: 594-8.
19. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116: 1413-9.
20. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.
21. George DK, Goldwurm S, MacDonald, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-8.
22. Ferranini E. Insulin resistance, iron and the liver. Lancet 2000; 355:2181-2.
23. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29: 664-9.
24. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
25. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinico-pathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-9.
26. Kim WR, Poterucha JJ, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-5.
27. Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
28. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-9.
29. Maher JJ. Alcoholic liver disease. In: Feldman M, Scharschmidt BF, Sleisinger MH, editors. Gastrointestinal and liver disease. 6th ed. Philadelphia: WB Saunders Company; 1998. p. 1199-214.
30. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in non-alcoholic steatohepatitis [letter]. Gastroenterology 1995;108: 1607.
31. Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in nonalcoholic steatohepatitis. Pathol Inst 2001;51:127-31.
32. Klein S. Total parenteral nutrition and the liver. In: Schiff L, Schiff ER, editors. Diseases of the liver. 7th ed. Philadelphia: Lippincott; 1993. p. 1505-16.
33. Tankurt E, Biberoglu S, Ellidokuz, Hekimsoy Z, Akpinar H, Comlekci A, et al. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999;31:963.
34. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107: 450-5.
35. Clain DJ, Lefkowitch JH. Fatty liver in morbid obesity. Gastroenterol Clin North Am 1987;16:239-52.
36. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
37. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996;80:1147-66.
38. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
39. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? [editorial]. Gastroenterology 1998;114:842-5.
40. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3-10.
41. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis leads to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200.
42. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29: 495-501.
43. Tilg H, Diehl AM. Mechanisms of disease: cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
44. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999;29:1131-8.
45. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. PNAS 1997;94:2557-62.
46. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-8.
47. Selzner M, Clavien PA. Failure of regeneration of the steatotic liver: disruption at two different levels in the regeneration pathway. Hepatology 2000;31:35-42.
48. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46:540-5.
49. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99: 1408-13.
50. Berkowitz D. Metabolic changes associated with obesity before and after weight reduction. JAMA 1964;187:103-10.
51. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Med 2000;6:998-1003.
52. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893-4.
53. Caldwell SH, Hespenheide EE, Redick JA, lezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:519-25.
54. Krentz AJ, Baily CJ, Melander A. Thiazolidinediones for type 2 diabetes. Br Med J 2000;321:252-3.
55. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol induced steatohepatitis. Hepatology 1996;23:1464-7.
56. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-8.
57. Abdelmalek MF, Angulo P, Jorgenson RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2001;96: 2711-7.
58. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000;50:722-7.